Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial / Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:6(2013). [10.1200/jco.2013.31.6_suppl.90]

Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial

Buti S;
2013-01-01

2013
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial / Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:6(2013). [10.1200/jco.2013.31.6_suppl.90]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906901
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact